Compound Research Guide

THCV-A, explained simply with PubMed links

This page translates THCV-A research into plain English: what scientists studied, what kind of evidence exists, where the source links are strong or limited, and which PubMed records support each bucket.

Launch set page

Read Evidence Overview Open Source Table

78research sources

22evidence buckets

PubMedlinked references

What this page is

A plain-English research page about THCV-A. It explains what researchers studied and links the PubMed or DOI sources.

How to use it

Read the overview first. If a sentence matters to you, open the PubMed link or source table below it.

Important limit

This page is education, not medical advice, dosing advice, or a recommendation to use cannabinoids.

Evidence Rows 108

Traceable statements carried into the source table.

Human Evidence 4

Rows where human participants, patients, or clinical evidence are visible.

Mechanisms 48

Biology, target, enzyme, receptor, or pharmacology rows.

Safety / Limits 26

Safety, tolerability, uncertainty, or insufficient-evidence context.

Evidence Overview

THCV-A has research behind it, but the bucket matters.

This page currently indexes 78 research sources across 22 evidence bucket(s). Read it as a map of what researchers have studied, not as a single bottom-line instruction. PMID 40270953

Human evidence 4 evidence rows

Human studies are separated from preclinical and mechanistic evidence so a reader can see where people were actually studied. PMID 40270953

Mechanisms 48 evidence rows

Mechanistic rows explain biological plausibility, receptor activity, enzyme activity, or pharmacology; they do not automatically prove an outcome in people. PMID 40270953

Safety and limits 26 evidence rows

Safety, tolerability, product quality, impairment, interactions, and higher-risk contexts stay visible instead of being treated as footnotes. PMID 40270953

Evidence Buckets

What the THCV-A research is usually about

Jump to source-backed table

safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns

THCV-A appears in rows studying safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns. It currently draws from 24 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 40270953

Receptor, target, metabolic, and pharmacology mechanisms

THCV-A appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 23 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 32899626

Appetite and metabolic outcomes

THCV-A appears in rows studying Appetite and metabolic outcomes. It currently draws from 13 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 33526143

Pain-related outcomes

THCV-A appears in rows studying Pain-related outcomes. It currently draws from 10 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 32899626

neurobehavioral, cognition, mood, reward, or THC-interaction outcomes

THCV-A appears in rows studying neurobehavioral, cognition, mood, reward, or THC-interaction outcomes. It currently draws from 9 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 40872492

receptor, target, or pharmacology mechanisms

THCV-A appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 5 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36257598

Reader Map

Evidence buckets before the source table

Grouped for readability

Bucket	Plain-English meaning	Evidence posture	Starting source
safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns	Grouped source-backed rows focused on safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (15), mechanistic or pharmacological (6), preclinical (2), preliminary human (1)	PMID 40270953
Receptor, target, metabolic, and pharmacology mechanisms	Grouped source-backed rows focused on Receptor, target, metabolic, and pharmacology mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (6), mechanistic or pharmacological (17)	PMID 32899626
Appetite and metabolic outcomes	Grouped source-backed rows focused on Appetite and metabolic outcomes, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (3), mechanistic or pharmacological (8), preliminary human (2)	PMID 33526143
Pain-related outcomes	Grouped source-backed rows focused on Pain-related outcomes, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (2), mechanistic or pharmacological (6), preclinical (1), preliminary human (1)	PMID 32899626
neurobehavioral, cognition, mood, reward, or THC-interaction outcomes	Grouped source-backed rows focused on neurobehavioral, cognition, mood, reward, or THC-interaction outcomes, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (4), preliminary human (1)	PMID 40872492
receptor, target, or pharmacology mechanisms	Grouped source-backed rows focused on receptor, target, or pharmacology mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (2)	PMID 36257598
Inflammation-related outcomes	Grouped source-backed rows focused on Inflammation-related outcomes, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: mechanistic or pharmacological (4)	PMID 37764262
receptor, target, or pharmacology mechanisms	Grouped source-backed rows focused on receptor, target, or pharmacology mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic and preclinical research summary: insufficient (1), mechanistic or pharmacological (1), preclinical (1)	PMID 34980287

Safety Reading Notes

Read safety context beside the research guide.

The THCV-A source set includes safety-context rows around safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 40270953

Developed but mixed human research summary: insufficient (15), mechanistic or pharmacological (6), preclinical (2), preliminary human (1)

PubMed For Dummies Article

THCV-A Evidence Review: the long-form source walk-through

Quick read

THCV-A currently has 108 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 40270953
The evidence classes most visible in the row language are mechanistic or pharmacological (54), insufficient (45), preliminary human (5), and preclinical (4). PMID 33526143
The study-design language most visible in the row language is Animal study (30), Narrative or expert review (25), Cellular or in vitro study (19), and other mapped categories (15). PMID 32899626
The repeated topics are safety, tolerability, adverse-event, impairment, THC-interaction, or formulat... (24), receptor, target, metabolic, or pharmacology mechanisms (23), Appetite and metabolic outcomes (13), receptor, target, or pharmacology mechanisms (13), and other mapped categories (35), which tells the reader where to start opening PubMed and DOI links. PMID 37764262

Start with the research question

THCV-A is built from 108 source-backed evidence row(s) and 78 research source(s). The current evidence classes read as mechanistic or pharmacological (54), insufficient (45), preliminary human (5), and preclinical (4), and the study-design language most often reads as Animal study (30), Narrative or expert review (25), Cellular or in vitro study (19), and other mapped categories (15). PMID 40270953

The row-level question is not simply whether THCV-A is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are safety, tolerability, adverse-event, impairment, THC-interaction, or formulat... (24), receptor, target, metabolic, or pharmacology mechanisms (23), Appetite and metabolic outcomes (13), receptor, target, or pharmacology mechanisms (13), and other mapped categories (35). PMID 32899626

Human evidence 4 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 27573936

Preclinical evidence 2 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 21740450

Mechanistic evidence 48 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 42196303

Limits and uncertainty 71 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 33230154

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 39968488

Where this page has the most source density

The largest bucket surfaced for this page is safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Receptor, target, metabolic, and pharmacology mechanisms, which gives readers another way to see what the literature repeatedly circles. PMID 40270953

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 32899626

Bucket chapters: what the literature is circling

safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns

24 research sources 24 rows (736-759) Developed but mixed human research summary: insufficient (15), mechanistic or pharmacological (6), preclinical (2), preliminary human (1)

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 40270953

Evidence row 736
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Nar... PMID 40270953
Evidence row 759
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interactio... PMID 23894589

Receptor, target, metabolic, and pharmacology mechanisms

23 research sources 23 rows (760-782) Mechanistic research summary: insufficient (6), mechanistic or pharmacological (17)

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 32899626

Evidence row 760
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: rec... PMID 32899626
Evidence row 782
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure:... PMID 30074247

Appetite and metabolic outcomes

13 research sources 13 rows (37-735) Developed but mixed human research summary: insufficient (3), mechanistic or pharmacological (8), preliminary human (2)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 33526143

Evidence row 37
THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabo... PMID 33526143
Evidence row 735
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes). PMID 32904155

Pain-related outcomes

10 research sources 10 rows (796-805) Developed but mixed human research summary: insufficient (2), mechanistic or pharmacological (6), preclinical (1), preliminary human (1)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 32899626

Evidence row 796
THCV studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 32899626
Evidence row 805
THCV studied for Pain-related outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 22155112

neurobehavioral, cognition, mood, reward, or THC-interaction outcomes

9 research sources 9 rows (787-795) Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (4), preliminary human (1)

Evidence row 787
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome... PMID 40872492
Evidence row 795
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 40525419

receptor, target, or pharmacology mechanisms

5 research sources 5 rows (201-287) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (2)

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 36257598

Evidence row 201
THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 36257598
Evidence row 287
THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 35566314

Inflammation-related outcomes

4 research sources 4 rows (783-786) Mechanistic research summary: mechanistic or pharmacological (4)

THCV-A appears in rows studying Inflammation-related outcomes. It currently draws from 4 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 37764262

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 37764262

Evidence row 783
THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: inflammat... PMID 37764262
Evidence row 786
THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-... PMID 36559009

receptor, target, or pharmacology mechanisms

3 research sources 3 rows (279-281) Mechanistic and preclinical research summary: insufficient (1), mechanistic or pharmacological (1), preclinical (1)

THCV-A appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 34980287

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 34980287

Evidence row 279
CBD studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharma... PMID 34980287
Evidence row 281
CBD studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40006604

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (4 row(s)), mechanistic evidence (48 row(s)), and safety/tolerability context (26 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 40270953

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 32899626

What this does and does not mean

It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 40363798
It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 11599601
It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 40872492

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 40270953

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 32899626

Source-reading checklist for THCV-A

Open the linked PubMed or DOI record. PMID 36257598
Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 17828291
Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 36827690
Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 37083031
Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 38162115

Source Notes

THCV-A source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

Evidence row 37
THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes). PMID 33526143
Evidence class: preliminary human; Study design: Human clinical study. Source: Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes.
Evidence row 38
THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes). PMID 40270953
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.
Evidence row 39
THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 74
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or pain-related outcomes). PMID 37764262
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
Evidence row 77
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes). PMID 27573936
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
Evidence row 78
THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes). PMID 21740450
Evidence class: insufficient; Study design: Narrative or expert review. Source: CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).
Evidence row 79
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes). PMID 42196303
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.
Evidence row 80
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 81
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes). PMID 39968488
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips.
Evidence row 82
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes). PMID 40363798
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The Impact of Major and Minor Phytocannabinoids on the Maintenance and Function of INS-1 β-Cells Under High-Glucose and High-Lipid Conditions.
Evidence row 83
THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes). PMID 11599601
Evidence class: preliminary human; Study design: Human clinical study. Source: Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.
Evidence row 167
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 40872492
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
Evidence row 201
THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 36257598
Evidence class: insufficient. Source: Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids.
Evidence row 204
THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 17828291
Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Evidence row 247
HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics). PMID 36827690
Evidence class: insufficient. Source: Isolation and Characterization of Impurities in Commercially Marketed Δ8-THC Products.
Evidence row 277
THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 37083031
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Antiviral activities of hemp cannabinoids.
Evidence row 278
THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 38162115
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain.
Evidence row 279
CBD studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34980287
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome.
Evidence row 280
CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34384142
Evidence class: preclinical; Study design: Animal study. Source: Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
Evidence row 281
CBD studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40006604
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics of Non-Psychotropic Phytocannabinoids.
Evidence row 282
CBCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 32824356
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus.
Evidence row 283
CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39808700
Evidence class: insufficient. Source: Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.
Evidence row 284
CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35306000
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
Evidence row 285
THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 37708768
Evidence class: insufficient. Source: Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid.
Evidence row 286
THCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39013926
Evidence class: insufficient. Source: Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'.
Evidence row 287
THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 35566314
Evidence class: insufficient. Source: Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures.
Evidence row 364
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 21175579
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
Evidence row 526
CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 37764262
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
Evidence row 639
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40872492
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
Evidence row 658
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 37764262
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
Evidence row 660
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40872492
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
Evidence row 711
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35628241
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.
Evidence row 713
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36769042
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.
Evidence row 733
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes). PMID 37764262
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
Evidence row 734
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes). PMID 37108282
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Tetrahydrocannabivarin (THCV) Protects Adipose-Derived Mesenchymal Stem Cells (ASC) against Endoplasmic Reticulum Stress Development and Reduces Inflammation during Adipogenesis.
Evidence row 735
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes). PMID 32904155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain.
Evidence row 736
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 40270953
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.
Evidence row 737
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 29842819
Evidence class: insufficient; Study design: Narrative or expert review. Source: Investigational cannabinoids in seizure disorders, what have we learned thus far?
Evidence row 738
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 27573936
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
Evidence row 739
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 21740450
Evidence class: insufficient; Study design: Narrative or expert review. Source: CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).
Evidence row 740
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 42196303
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.
Evidence row 741
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 38862388
Evidence class: insufficient. Source: Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry.
Evidence row 742
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 40872492
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
Evidence row 743
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 37630401
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.
Evidence row 744
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 37721989
Evidence class: preclinical; Study design: Animal study. Source: Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats.
Evidence row 745
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 37721990
Evidence class: preliminary human; Study design: Human clinical study. Source: A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants.
Evidence row 746
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 41947574
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.
Evidence row 747
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 42151379
Evidence class: preclinical; Study design: Animal study. Source: Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain.
Evidence row 748
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 37697897
Evidence class: insufficient. Source: Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing.
Evidence row 749
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 35799289
Evidence class: insufficient. Source: Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies.
Evidence row 750
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 25542687
Evidence class: insufficient; Study design: Human clinical study. Source: Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.
Evidence row 751
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 26577065
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.
Evidence row 752
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Case report or case series; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 37305187
Evidence class: mechanistic or pharmacological; Study design: Case report or case series. Source: Hair Regrowth with Novel Hemp Extract: A Case Series.
Evidence row 753
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 40131178
Evidence class: insufficient. Source: Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products.
Evidence row 754
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 35303507
Evidence class: insufficient; Study design: Animal study. Source: Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents.
Evidence row 755
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 23712280
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.
Evidence row 756
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 31549358
Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
Evidence row 757
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 36280497
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies.
Evidence row 758
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 35585089
Evidence class: insufficient. Source: Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath.
Evidence row 759
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 23894589
Evidence class: insufficient. Source: Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile.
Evidence row 760
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 761
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 42196303
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.
Evidence row 762
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40872492
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
Evidence row 763
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 17828291
Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Evidence row 764
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 765
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21175579
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
Evidence row 766
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28120231
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
Evidence row 767
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Systematic review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25257544
Evidence class: insufficient; Study design: Systematic review. Source: Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
Evidence row 768
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 16205722
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
Evidence row 769
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28087250
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoids in the treatment of epilepsy.
Evidence row 770
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 41008636
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.
Evidence row 771
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 30170189
Evidence class: mechanistic or pharmacological. Source: Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.
Evidence row 772
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 31454413
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.
Evidence row 773
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 20590571
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.
Evidence row 774
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 17245367
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
Evidence row 775
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 23902479
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Evidence row 776
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 18311186
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum.
Evidence row 777
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25542687
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.
Evidence row 778
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 38691614
Evidence class: mechanistic or pharmacological. Source: TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site.
Evidence row 779
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 35714693
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Loratadine, an antihistaminic drug, suppresses the proliferation of endometrial stromal cells by inhibition of TRPV2.
Evidence row 780
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21726418
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
Evidence row 781
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 34500785
Evidence class: mechanistic or pharmacological. Source: An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.
Evidence row 782
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 30074247
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.
Evidence row 783
THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or immune outcomes). PMID 37764262
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
Evidence row 784
THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 785
THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or immune outcomes). PMID 33446817
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages.
Evidence row 786
THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or immune outcomes). PMID 36559009
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models.
Evidence row 787
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 40872492
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
Evidence row 788
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 31454413
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.
Evidence row 789
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 25542687
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.
Evidence row 790
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 28109780
Evidence class: insufficient; Study design: Narrative or expert review. Source: Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.
Evidence row 791
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 26577065
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.
Evidence row 792
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 23109356
Evidence class: insufficient; Study design: Human clinical study. Source: Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Evidence row 793
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 26362774
Evidence class: preliminary human; Study design: Human clinical study. Source: The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.
Evidence row 794
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 37532722
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Molecular pathway and structural mechanism of human oncochannel TRPV6 inhibition by the phytocannabinoid tetrahydrocannabivarin.
Evidence row 795
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 40525419
Evidence class: mechanistic or pharmacological. Source: Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments.
Evidence row 796
THCV studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 797
THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: pain-related outcomes). PMID 37764262
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
Evidence row 798
THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 799
THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (outcome measure: pain-related outcomes). PMID 19679411
Evidence class: mechanistic or pharmacological. Source: Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Evidence row 800
THCV studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 42151379
Evidence class: preclinical; Study design: Animal study. Source: Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain.
Evidence row 801
THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 20590571
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.
Evidence row 802
THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 17245367
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
Evidence row 803
THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (outcome measure: pain-related outcomes). PMID 41135090
Evidence class: mechanistic or pharmacological. Source: Cannabivarin and tetrahydrocannabivarin modulate nociception via vanilloid channels and cannabinoid-like receptors in Caenorhabditis elegans.
Evidence row 804
THCV studied for Pain-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: pain-related outcomes). PMID 30350275
Evidence class: preliminary human. Source: Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry.
Evidence row 805
THCV studied for Pain-related outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 22155112
Evidence class: insufficient; Study design: Narrative or expert review. Source: The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications.
Evidence row 863
THC modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 17828291
Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Evidence row 1050
THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21175579
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.

Source Trail

Source-backed evidence table and references

78 research sources

This section is the technical source layer under the overview. It keeps grouped evidence buckets, evidence rows, PubMed or DOI links, related pages, and references visible for audit and revision.

Plain-Language Summary

THCV-A has 108 source-backed evidence row(s) from 78 source(s). The current page should separate outcomes, mechanisms, formulation context, and safety signals.

Identity

Canonical name: thcv-a
Type: compound
Subtype: phytocannabinoid_acid
Description: Not recorded

Evidence Snapshot

Evidence rows: 108
Sources: 78
Evidence classes: insufficient (45), mechanistic or pharmacological (54), preclinical (4), preliminary human (5)
Draft sections: human evidence (4), mechanistic evidence (48), preclinical evidence (2), safety (26), uncertainty (28)

Key Draft Sections

Human evidence: 4 evidence row(s).
Safety and tolerability: 26 evidence row(s).
Uncertainty and gaps: 28 evidence row(s).
Preclinical evidence: 2 evidence row(s).
Mechanistic evidence: 48 evidence row(s).

Studied Outcomes And Mechanisms

Subject	Relationship	Object Or Focus	Evidence Summary	Sources	Evidence Rows
CBC	studied for	Inflammation-related outcomes	Mechanistic research summary: mechanistic or pharmacological (1)	1	74
CBC	studied for	receptor, target, or pharmacology mechanisms	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (283-284)
CBC	modulates	receptor, transporter, target, metabolic, or pharmacology mechanisms	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (658-660)
CBC	studied for	safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	639
CBC	studied for	Skin and inflammatory dermatology	Mechanistic research summary: mechanistic or pharmacological (2)	2	2 rows (711-713)
CBCA	studied for	receptor, target, or pharmacology mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	282
CBD	studied for	receptor, target, or pharmacology mechanisms	Mechanistic and preclinical research summary: insufficient (1), mechanistic or pharmacological (1), preclinical (1)	3	3 rows (279-281)
CBG	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	167
CBN	studied for	Skin and inflammatory dermatology	Mechanistic research summary: mechanistic or pharmacological (1)	1	526
HHC	studied for	Rare phytocannabinoids research topics	Mapped evidence with interpretation limits: insufficient (1)	1	247
THC	modulates	CB2	Mapped evidence with interpretation limits: insufficient (1)	1	863
THC	studied for	receptor, target, or pharmacology mechanisms	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (2)	5	5 rows (201-287)
THC	modulates	receptor, target, or pharmacology mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	204
THC	modulates	TRP channel activity or ionotropic cannabinoid target mechanisms	Mechanistic research summary: mechanistic or pharmacological (1)	1	364
THC	modulates	TRPM8	Mechanistic research summary: mechanistic or pharmacological (1)	1	1050
THCA	studied for	receptor, target, or pharmacology mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	286
THCV	studied for	Appetite and metabolic outcomes	Developed but mixed human research summary: insufficient (3), mechanistic or pharmacological (8), preliminary human (2)	13	13 rows (37-735)
THCV	studied for	Inflammation-related outcomes	Mechanistic research summary: mechanistic or pharmacological (4)	4	4 rows (783-786)
THCV	studied for	neurobehavioral, cognition, mood, reward, or THC-interaction outcomes	Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (4), preliminary human (1)	9	9 rows (787-795)
THCV	studied for	Pain-related outcomes	Developed but mixed human research summary: insufficient (2), mechanistic or pharmacological (6), preclinical (1), preliminary human (1)	10	10 rows (796-805)
THCV	modulates	receptor, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (6), mechanistic or pharmacological (17)	23	23 rows (760-782)
THCV	studied for	safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns	Developed but mixed human research summary: insufficient (15), mechanistic or pharmacological (6), preclinical (2), preliminary human (1)	24	24 rows (736-759)

Source-Backed Evidence Table

Evidence Row	Statement	Source
37	THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes).	Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes.PubMed 33526143 DOI 10.1186/s42238-020-0016-7
38	THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes).	The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.PubMed 40270953 DOI 10.3934/neuroscience.2025003
39	THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
74	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or pain-related outcomes).	Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.PubMed 37764262 DOI 10.3390/molecules28186487
77	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes).	Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.PubMed 27573936 DOI 10.2337/dc16-0650
78	THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes).	CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).PubMed 21740450 DOI 10.1111/j.1365-2710.2011.01284.x
79	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes).	SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
80	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
81	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes).	Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips.PubMed 39968488 DOI 10.26828/cannabis/2024/000206
82	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes).	The Impact of Major and Minor Phytocannabinoids on the Maintenance and Function of INS-1 β-Cells Under High-Glucose and High-Lipid Conditions.PubMed 40363798 DOI 10.3390/molecules30091991
83	THCV studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related or metabolic outcomes).	Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.PubMed 11599601 DOI 10.1093/jat/25.7.565
167	CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.PubMed 40872492 DOI 10.3390/ph18081101
201	THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms).	Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids.PubMed 36257598 DOI 10.1055/a-1962-8165
204	THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
247	HHC studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics).	Isolation and Characterization of Impurities in Commercially Marketed Δ8-THC Products.PubMed 36827690 DOI 10.1021/acs.jnatprod.2c01008
277	THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms).	Antiviral activities of hemp cannabinoids.PubMed 37083031 DOI 10.1042/cs20220193
278	THC studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain.PubMed 38162115 DOI 10.1093/function/zqad069
279	CBD studied for receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome.PubMed 34980287 DOI 10.1186/s42238-021-00113-w
280	CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.PubMed 34384142 DOI 10.1111/bph.15661
281	CBD studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Pharmacokinetics of Non-Psychotropic Phytocannabinoids.PubMed 40006604 DOI 10.3390/pharmaceutics17020236
282	CBCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms).	Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus.PubMed 32824356 DOI 10.3390/antibiotics9080523
283	CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms).	Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.PubMed 39808700 DOI 10.1021/acssynbio.4c00721
284	CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms).	In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
285	THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms).	Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid.PubMed 37708768 DOI 10.1016/j.talanta.2023.125161
286	THCA studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms).	Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'.PubMed 39013926 DOI 10.1038/s41598-024-66420-3
287	THC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms).	Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures.PubMed 35566314 DOI 10.3390/molecules27092965
364	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.PubMed 21175579 DOI 10.1111/j.1476-5381.2010.01166.x
526	CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes).	Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.PubMed 37764262 DOI 10.3390/molecules28186487
639	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.PubMed 40872492 DOI 10.3390/ph18081101
658	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.PubMed 37764262 DOI 10.3390/molecules28186487
660	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.PubMed 40872492 DOI 10.3390/ph18081101
711	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.PubMed 35628241 DOI 10.3390/ijms23105430
713	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.PubMed 36769042 DOI 10.3390/ijms24032721
733	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes).	Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.PubMed 37764262 DOI 10.3390/molecules28186487
734	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes).	Tetrahydrocannabivarin (THCV) Protects Adipose-Derived Mesenchymal Stem Cells (ASC) against Endoplasmic Reticulum Stress Development and Reduces Inflammation during Adipogenesis.PubMed 37108282 DOI 10.3390/ijms24087120
735	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes).	High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain.PubMed 32904155 DOI 10.7717/peerj.9811
736	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.PubMed 40270953 DOI 10.3934/neuroscience.2025003
737	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Investigational cannabinoids in seizure disorders, what have we learned thus far?PubMed 29842819 DOI 10.1080/13543784.2018.1482275
738	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.PubMed 27573936 DOI 10.2337/dc16-0650
739	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).PubMed 21740450 DOI 10.1111/j.1365-2710.2011.01284.x
740	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
741	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry.PubMed 38862388 DOI 10.1021/acs.analchem.3c05879
742	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.PubMed 40872492 DOI 10.3390/ph18081101
743	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.PubMed 37630401 DOI 10.3390/molecules28166149
744	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats.PubMed 37721989 DOI 10.1089/can.2023.0049
745	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants.PubMed 37721990 DOI 10.1089/can.2023.0038
746	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.PubMed 41947574 DOI 10.1093/alcalc/agag019
747	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain.PubMed 42151379 DOI 10.1038/s41598-026-51275-7
748	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing.PubMed 37697897 DOI 10.1093/jat/bkad068
749	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies.PubMed 35799289 DOI 10.1186/s42238-022-00146-9
750	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.PubMed 25542687 DOI 10.1093/ijnp/pyu094
751	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.PubMed 26577065 DOI 10.1177/0269881115615104
752	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Case report or case series; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Hair Regrowth with Novel Hemp Extract: A Case Series.PubMed 37305187 DOI 10.4103/ijt.ijt_34_22
753	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products.PubMed 40131178 DOI 10.1080/02791072.2025.2484376
754	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents.PubMed 35303507 DOI 10.1016/j.intimp.2022.108693
755	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.PubMed 23712280 DOI 10.1038/nutd.2013.9
756	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.PubMed 31549358 DOI 10.1007/s40263-019-00664-w
757	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies.PubMed 36280497 DOI 10.1016/j.tem.2022.08.003
758	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath.PubMed 35585089 DOI 10.1038/s41598-022-11481-5
759	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile.PubMed 23894589 DOI 10.1371/journal.pone.0070052
760	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
761	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
762	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.PubMed 40872492 DOI 10.3390/ph18081101
763	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
764	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
765	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.PubMed 21175579 DOI 10.1111/j.1476-5381.2010.01166.x
766	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
767	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Systematic review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.PubMed 25257544 DOI 10.1111/bph.12944
768	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.PubMed 16205722 DOI 10.1038/sj.bjp.0706414
769	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pharmacology of cannabinoids in the treatment of epilepsy.PubMed 28087250 DOI 10.1016/j.yebeh.2016.11.016
770	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.PubMed 41008636 DOI 10.3390/biom15091329
771	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.PubMed 30170189 DOI 10.1016/j.phrs.2018.08.021
772	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.PubMed 31454413 DOI 10.1111/bph.14844
773	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.PubMed 20590571 DOI 10.1111/j.1476-5381.2010.00756.x
774	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.PubMed 17245367 DOI 10.1038/sj.bjp.0707124
775	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.PubMed 23902479 DOI 10.1111/bph.12322
776	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum.PubMed 18311186 DOI 10.1038/bjp.2008.57
777	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.PubMed 25542687 DOI 10.1093/ijnp/pyu094
778	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site.PubMed 38691614 DOI 10.1126/sciadv.adn2453
779	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Loratadine, an antihistaminic drug, suppresses the proliferation of endometrial stromal cells by inhibition of TRPV2.PubMed 35714693 DOI 10.1016/j.ejphar.2022.175086
780	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.PubMed 21726418 DOI 10.1111/j.1748-1716.2011.02338.x
781	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.PubMed 34500785 DOI 10.3390/molecules26175352
782	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.PubMed 30074247 DOI 10.1111/bph.14460
783	THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or immune outcomes).	Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.PubMed 37764262 DOI 10.3390/molecules28186487
784	THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
785	THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or immune outcomes).	Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages.PubMed 33446817 DOI 10.1038/s41598-021-81049-2
786	THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or immune outcomes).	Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models.PubMed 36559009 DOI 10.3390/ph15121559
787	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.PubMed 40872492 DOI 10.3390/ph18081101
788	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.PubMed 31454413 DOI 10.1111/bph.14844
789	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.PubMed 25542687 DOI 10.1093/ijnp/pyu094
790	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.PubMed 28109780 DOI 10.1016/j.yebeh.2016.11.020
791	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.PubMed 26577065 DOI 10.1177/0269881115615104
792	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Medical use of cannabis. Cannabidiol: a new light for schizophrenia?PubMed 23109356 DOI 10.1002/dta.1425
793	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.PubMed 26362774 DOI 10.1093/ijnp/pyv092
794	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Molecular pathway and structural mechanism of human oncochannel TRPV6 inhibition by the phytocannabinoid tetrahydrocannabivarin.PubMed 37532722 DOI 10.1038/s41467-023-40362-2
795	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments.PubMed 40525419 DOI 10.2174/0115734064318657240822064240
796	THCV studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
797	THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: pain-related outcomes).	Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.PubMed 37764262 DOI 10.3390/molecules28186487
798	THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
799	THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (outcome measure: pain-related outcomes).	Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.PubMed 19679411 DOI 10.1016/j.drugalcdep.2009.06.009
800	THCV studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain.PubMed 42151379 DOI 10.1038/s41598-026-51275-7
801	THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.PubMed 20590571 DOI 10.1111/j.1476-5381.2010.00756.x
802	THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.PubMed 17245367 DOI 10.1038/sj.bjp.0707124
803	THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (outcome measure: pain-related outcomes).	Cannabivarin and tetrahydrocannabivarin modulate nociception via vanilloid channels and cannabinoid-like receptors in Caenorhabditis elegans.PubMed 41135090 DOI 10.1139/cjpp-2025-0243
804	THCV studied for Pain-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: pain-related outcomes).	Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry.PubMed 30350275 DOI 10.1007/978-1-4939-8823-5_2
805	THCV studied for Pain-related outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: pain-related outcomes).	The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications.PubMed 22155112 DOI 10.1016/j.ajpath.2011.11.003
863	THC modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
1050	THC modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.PubMed 21175579 DOI 10.1111/j.1476-5381.2010.01166.x

Appetite and metabolic outcomes
CB2
CBC
CBCA
CBD
CBG
CBN
HHC
Inflammation-related outcomes
Pain-related outcomes
Skin and inflammatory dermatology
THC
THCA
THCV
TRPM8

References

Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes.PubMed 33526143 DOI 10.1186/s42238-020-0016-7
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.PubMed 40270953 DOI 10.3934/neuroscience.2025003
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.PubMed 37764262 DOI 10.3390/molecules28186487
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.PubMed 27573936 DOI 10.2337/dc16-0650
CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).PubMed 21740450 DOI 10.1111/j.1365-2710.2011.01284.x
SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips.PubMed 39968488 DOI 10.26828/cannabis/2024/000206
The Impact of Major and Minor Phytocannabinoids on the Maintenance and Function of INS-1 β-Cells Under High-Glucose and High-Lipid Conditions.PubMed 40363798 DOI 10.3390/molecules30091991
Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.PubMed 11599601 DOI 10.1093/jat/25.7.565
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.PubMed 40872492 DOI 10.3390/ph18081101
Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids.PubMed 36257598 DOI 10.1055/a-1962-8165
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
Isolation and Characterization of Impurities in Commercially Marketed Δ8-THC Products.PubMed 36827690 DOI 10.1021/acs.jnatprod.2c01008
Antiviral activities of hemp cannabinoids.PubMed 37083031 DOI 10.1042/cs20220193
Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain.PubMed 38162115 DOI 10.1093/function/zqad069
Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome.PubMed 34980287 DOI 10.1186/s42238-021-00113-w
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.PubMed 34384142 DOI 10.1111/bph.15661
Pharmacokinetics of Non-Psychotropic Phytocannabinoids.PubMed 40006604 DOI 10.3390/pharmaceutics17020236
Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus.PubMed 32824356 DOI 10.3390/antibiotics9080523
Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.PubMed 39808700 DOI 10.1021/acssynbio.4c00721
In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid.PubMed 37708768 DOI 10.1016/j.talanta.2023.125161
Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'.PubMed 39013926 DOI 10.1038/s41598-024-66420-3
Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures.PubMed 35566314 DOI 10.3390/molecules27092965
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.PubMed 21175579 DOI 10.1111/j.1476-5381.2010.01166.x
Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.PubMed 35628241 DOI 10.3390/ijms23105430
Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.PubMed 36769042 DOI 10.3390/ijms24032721
Tetrahydrocannabivarin (THCV) Protects Adipose-Derived Mesenchymal Stem Cells (ASC) against Endoplasmic Reticulum Stress Development and Reduces Inflammation during Adipogenesis.PubMed 37108282 DOI 10.3390/ijms24087120
High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain.PubMed 32904155 DOI 10.7717/peerj.9811
Investigational cannabinoids in seizure disorders, what have we learned thus far?PubMed 29842819 DOI 10.1080/13543784.2018.1482275
Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry.PubMed 38862388 DOI 10.1021/acs.analchem.3c05879
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.PubMed 37630401 DOI 10.3390/molecules28166149
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats.PubMed 37721989 DOI 10.1089/can.2023.0049
A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants.PubMed 37721990 DOI 10.1089/can.2023.0038
Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.PubMed 41947574 DOI 10.1093/alcalc/agag019
Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain.PubMed 42151379 DOI 10.1038/s41598-026-51275-7
Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing.PubMed 37697897 DOI 10.1093/jat/bkad068
Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies.PubMed 35799289 DOI 10.1186/s42238-022-00146-9
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.PubMed 25542687 DOI 10.1093/ijnp/pyu094
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.PubMed 26577065 DOI 10.1177/0269881115615104
Hair Regrowth with Novel Hemp Extract: A Case Series.PubMed 37305187 DOI 10.4103/ijt.ijt_34_22
Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products.PubMed 40131178 DOI 10.1080/02791072.2025.2484376
Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents.PubMed 35303507 DOI 10.1016/j.intimp.2022.108693
The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.PubMed 23712280 DOI 10.1038/nutd.2013.9
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.PubMed 31549358 DOI 10.1007/s40263-019-00664-w
Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies.PubMed 36280497 DOI 10.1016/j.tem.2022.08.003
Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath.PubMed 35585089 DOI 10.1038/s41598-022-11481-5
Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile.PubMed 23894589 DOI 10.1371/journal.pone.0070052
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.PubMed 25257544 DOI 10.1111/bph.12944
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.PubMed 16205722 DOI 10.1038/sj.bjp.0706414
Pharmacology of cannabinoids in the treatment of epilepsy.PubMed 28087250 DOI 10.1016/j.yebeh.2016.11.016
Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.PubMed 41008636 DOI 10.3390/biom15091329
Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.PubMed 30170189 DOI 10.1016/j.phrs.2018.08.021
Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.PubMed 31454413 DOI 10.1111/bph.14844
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.PubMed 20590571 DOI 10.1111/j.1476-5381.2010.00756.x
The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.PubMed 17245367 DOI 10.1038/sj.bjp.0707124
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.PubMed 23902479 DOI 10.1111/bph.12322
The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum.PubMed 18311186 DOI 10.1038/bjp.2008.57
TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site.PubMed 38691614 DOI 10.1126/sciadv.adn2453
Loratadine, an antihistaminic drug, suppresses the proliferation of endometrial stromal cells by inhibition of TRPV2.PubMed 35714693 DOI 10.1016/j.ejphar.2022.175086
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.PubMed 21726418 DOI 10.1111/j.1748-1716.2011.02338.x
An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.PubMed 34500785 DOI 10.3390/molecules26175352
Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.PubMed 30074247 DOI 10.1111/bph.14460
Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages.PubMed 33446817 DOI 10.1038/s41598-021-81049-2
Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models.PubMed 36559009 DOI 10.3390/ph15121559
Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.PubMed 28109780 DOI 10.1016/j.yebeh.2016.11.020
Medical use of cannabis. Cannabidiol: a new light for schizophrenia?PubMed 23109356 DOI 10.1002/dta.1425
The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.PubMed 26362774 DOI 10.1093/ijnp/pyv092
Molecular pathway and structural mechanism of human oncochannel TRPV6 inhibition by the phytocannabinoid tetrahydrocannabivarin.PubMed 37532722 DOI 10.1038/s41467-023-40362-2
Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments.PubMed 40525419 DOI 10.2174/0115734064318657240822064240
Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.PubMed 19679411 DOI 10.1016/j.drugalcdep.2009.06.009
Cannabivarin and tetrahydrocannabivarin modulate nociception via vanilloid channels and cannabinoid-like receptors in Caenorhabditis elegans.PubMed 41135090 DOI 10.1139/cjpp-2025-0243
Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry.PubMed 30350275 DOI 10.1007/978-1-4939-8823-5_2
The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications.PubMed 22155112 DOI 10.1016/j.ajpath.2011.11.003

THCV-A has research behind it, but the bucket matters.

What the THCV-A research is usually about

safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns

Receptor, target, metabolic, and pharmacology mechanisms

Appetite and metabolic outcomes

Pain-related outcomes

neurobehavioral, cognition, mood, reward, or THC-interaction outcomes

receptor, target, or pharmacology mechanisms

Evidence buckets before the source table

Keep reading around this topic

Read safety context beside the research guide.

THCV-A Evidence Review: the long-form source walk-through

Start with the research question

Where this page has the most source density

Bucket chapters: what the literature is circling

safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns

Receptor, target, metabolic, and pharmacology mechanisms

Appetite and metabolic outcomes

Pain-related outcomes

neurobehavioral, cognition, mood, reward, or THC-interaction outcomes

receptor, target, or pharmacology mechanisms

Inflammation-related outcomes

receptor, target, or pharmacology mechanisms

Human evidence, mechanisms, and safety are different lanes

What this does and does not mean

How to use the source table

Source-reading checklist for THCV-A

THCV-A source-by-source reading notes

Source-backed evidence table and references

Plain-Language Summary

Identity

Evidence Snapshot

Key Draft Sections

Studied Outcomes And Mechanisms

Source-Backed Evidence Table

Related Pages

References